Scientific research progress of COVID‐19/SARS‐CoV‐2 in the first five months

• Published in: Journal of cellular and molecular medicine Vol. 24; no. 12; pp. 6558 - 6570
• Main Authors: Li, Hua, Liu, Zhe, Ge, Junbo
• Format: Journal Article
• Language: English
• Published: England John Wiley & Sons, Inc 01.06.2020; John Wiley and Sons Inc
• Subjects: Adenosine Monophosphate - analogs & derivatives; Adenosine Monophosphate - therapeutic use; Age; Alanine - analogs & derivatives; Alanine - therapeutic use; Amides - therapeutic use; Amino acids; Angiotensin-Converting Enzyme 2; Angiotensin-Converting Enzyme Inhibitors - therapeutic use; Antiviral Agents - therapeutic use; Asymptomatic; Betacoronavirus - drug effects; Betacoronavirus - immunology; Betacoronavirus - pathogenicity; Chronic illnesses; Clinical Laboratory Techniques; Coronaviridae; Coronavirus Infections - diagnosis; Coronavirus Infections - drug therapy; Coronavirus Infections - epidemiology; Coronavirus Infections - immunology; Coronavirus Infections - prevention & control; Coronavirus Infections - therapy; Coronaviruses; COVID-19; COVID-19 Serotherapy; COVID-19 Testing; COVID-19 Vaccines; Disease Progression; Disease transmission; Epidemics; Epidemiology; Fatalities; Gene Expression Regulation; Genomes; Host-Pathogen Interactions - genetics; Host-Pathogen Interactions - immunology; Humans; Immunization, Passive - methods; Infections; Medical research; Mutation; Pandemics; Pathogenesis; Peptidyl-Dipeptidase A - genetics; Peptidyl-Dipeptidase A - immunology; Phylogenetics; Phylogeny; Pneumonia, Viral - diagnosis; Pneumonia, Viral - drug therapy; Pneumonia, Viral - epidemiology; Pneumonia, Viral - immunology; Proteins; Pyrazines - therapeutic use; Review; Reviews; Ribonucleic acid; RNA; SARS-CoV-2; Severe acute respiratory syndrome coronavirus 2; Severity of Illness Index; Spike Glycoprotein, Coronavirus - antagonists & inhibitors; Spike Glycoprotein, Coronavirus - genetics; Spike Glycoprotein, Coronavirus - immunology; Studies; Viral infections; Viral Vaccines - biosynthesis; Viruses; United Kingdom > UK; China
• ISSN: 1582-1838; 1582-4934; 1582-4934
• DOI: 10.1111/jcmm.15364

A cluster of pneumonia (COVID‐19) cases have been found in Wuhan China in late December, 2019, and subsequently, a novel coronavirus with a positive stranded RNA was identified to be the aetiological virus (severe acute respiratory syndrome coronavirus 2, SARS‐CoV‐2), which has a phylogenetic similarity to severe acute respiratory syndrome coronavirus (SARS‐CoV). SARS‐CoV‐2 transmits mainly through droplets and close contact and the elder or people with chronic diseases are high‐risk population. People affected by SARS‐CoV‐2 can be asymptomatic, which brings about more difficulties to control the transmission. COVID‐19 has become pandemic rapidly after onset, and so far the infected people have been above 2 000 000 and more than 130 000 died worldwide according to COVID‐19 situation dashboard of World Health Organization (https://covid19.who.int). Here, we summarized the current known knowledge regarding epidemiological, pathogenesis, pathology, clinical features, comorbidities and treatment of COVID‐19/ SARS‐CoV‐2 as reference for the prevention and control COVID‐19.